Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
7
×
Tags
boston
7
×
boston blog main
boston top stories
life sciences
national blog main
national top stories
7
×
san diego blog main
7
×
new york blog main
biotech
fda
san diego top stories
san francisco blog main
clinical trials
new york top stories
akcea therapeutics
alnylam pharmaceuticals
drugs
hereditary transthyretin amyloidosis
inotersen
medical devices
patisiran
san francisco top stories
tafamidis
boulder/denver blog main
detroit blog main
indiana blog main
onpattro
pfizer
raleigh-durham blog main
rna interference
seattle blog main
startups
texas blog main
vyndaqel
wisconsin blog main
38 studios
accelerator
aidan petrie
andrew fire
antibiotics
What
alnylam
drug
fda
medicine
ago
biotechs
device
ipo
ipos
life
make
rna
rnai
science
time
uses
way
acquire
adding
afternoon
alnylam’s
approve
approved
approves
atrial
awaits
better
biological
boston
boston’s
business
capital
cells
chose
city
close
company
considering
continues
crossed
Language
unset
Current search:
photo
×
boston
×
" national top stories "
×
" san diego blog main "
×
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision
@xconomy.com
5 years ago
Boston Scientific Continues M&A Streak with $202M Deal for Cryterion